LONA
LeonaBio Inc. Common Stock (LONA)
Healthcare • NASDAQ • $10.04+1.83%
- Symbol
- LONA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $10.04
- Daily Change
- +1.83%
- Market Cap
- $94.31M
- Trailing P/E
- N/A
- Forward P/E
- N/A
- 52W High
- $14.21
- 52W Low
- $2.51
- Analyst Target
- $16.00
- Dividend Yield
- N/A
- Beta
- N/A
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is i…
Company websiteResearch LONA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.